Intermittent Claudication - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Intermittent Claudication - Pipeline Review, H2 2016

Intermittent Claudication - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Intermittent Claudication - Pipeline Review, H2 2016
Published Jul 13, 2016
51 pages — Published Jul 13, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Intermittent Claudication - Pipeline Review, H2 2016, provides an overview of the Intermittent Claudication pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Intermittent Claudication, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Intermittent Claudication
- The report reviews pipeline therapeutics for Intermittent Claudication by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Intermittent Claudication therapeutics and enlists all their major and minor projects
- The report assesses Intermittent Claudication therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Intermittent Claudication

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Intermittent Claudication
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline proje

  
Source:
Document ID
GMDHC8221IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Intermittent Claudication Overview61
Therapeutics Development71
  Pipeline Products for Intermittent Claudication Overview71
Intermittent Claudication Therapeutics under Development by Companies81
Intermittent Claudication Pipeline Products Glance92
  Clinical Stage Products91
  Early Stage Products101
Intermittent Claudication Products under Development by Companies111
Intermittent Claudication Companies Involved in Therapeutics Development124
  ID Pharma Co., Ltd.121
  Kowa Company, Ltd.131
  Nuo Therapeutics, Inc.141
  Pluristem Therapeutics Inc.151
Intermittent Claudication Therapeutics Assessment169
  Assessment by Monotherapy Products161
  Assessment by Target172
  Assessment by Mechanism of Action192
  Assessment by Route of Administration212
  Assessment by Molecule Type232
Drug Profiles2516
  ALD-301 Drug Profile253
  DVC-10101 Drug Profile281
  K-134 Drug Profile292
  LT-0101 Drug Profile311
  PLX-PAD Drug Profile329
Intermittent Claudication Dormant Projects411
Intermittent Claudication Discontinued Products421
Intermittent Claudication Product Development Milestones437
  Featured News &Press Releases431
    May 16, 2016: Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial431
    Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications431
    Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea441
    Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel441
    Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication Study441
    Jul 08, 2013: Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells451
    Jun 04, 2013: Pluristem To Receive Clinical-hold Notice From FDA For US Phase II Intermittent Claudication Study451
    Jan 15, 2013: Pluristem Receives Approval To Expand Phase II Clinical Trial In Intermittent Claudication To Germany451
    Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells461
    Aug 13, 2012: Pluristem Moves Intermittent Claudication Indication Forward in Germany Through Collaboration With Cato Research461
    Jul 18, 2012: Pluristem Partners With CPC Clinical Research For Peripheral Artery Disease Study471
    Apr 17, 2012: Pluristem Receives FDA Clearance For Phase II Clinical Trial In Intermittent Claudication471
    Jan 11, 2012: Kowa Initiates Japan Phase IIb Clinical Trials Of Anti-Platelet Agent K-134481
    Dec 02, 2011: Kowa Releases Japan Phase IIb Clinical Trials Data Of Anti-Platelet Agent, K-134481
    Nov 10, 2011: Kowa Announces Efficacy And Safety Of K-134 For Treatment Of Intermittent Claudication In AHA 2011482
Appendix502
  Methodology501
  Coverage501
  Secondary Research501
  Primary Research501
  Expert Panel Validation501
  Contact Us501
  Disclaimer511

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Intermittent Claudication - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Intermittent-Claudication-Pipeline-Review-H2-2016-2088-16156>
  
APA:
Global Markets Direct - Market Research. (2016). Intermittent Claudication - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Intermittent-Claudication-Pipeline-Review-H2-2016-2088-16156>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.